Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Nirsum Laboratories presents prodrugs of opioid receptor antagonists

Dec. 1, 2020

BP-C2 mitigates radiation-induced gastrointestinal syndrome in mice

Oct. 16, 2020

Selective PDEB inhibitor shows promising preclinical results for the treatment of cocaine addiction

Oct. 9, 2020

Sobrera and Recipharm collaborate on formulation development of SO-001 for alcohol use disorder

Sep. 29, 2020

Microglial pruning under the influence links alcohol to anxiety

Sep. 28, 2020

Proniras receives NIDA grant to pursue development of tezampanel for opioid withdrawal

Sep. 18, 2020

Embera begins phase II study of EMB-001 for cocaine use disorder

Sep. 1, 2020

FDA clears IND for phase II study of TNX-102 SL

Aug. 7, 2020

Indivior begins first-in-human study of INDV-2000 for opioid dependence

July 9, 2020

Idorsia Pharmaceuticals identifies new Ox1-R and Ox2-R antagonists

June 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...